Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

Stamford: SpringWorks Therapeutics, Inc., a healthcare company of Merck, has received marketing authorization from the ...

Fidelity Enhanced Large Cap Core is a growth-focused fund with tech exposure, balanced strategy, and strong risk-adjusted ...

"Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since ...

AbbVie ABBV is known for its strong immunology franchise comprising blockbuster drugs like Skyrizi, Rinvoq and Humira.

The Dow Jones Industrial Average is trading up Friday morning with shares of Boeing and Honeywell seeing positive gains for the price-weighted average. Shares of Boeing and Honeywell have contributed ...

BioNxt fast-tracks US patent for multiple sclerosis drug and secures broad platform IP covering autoimmune neurology pipeline: Vancouver, BC Friday, August 22, 2025, 09:00 Hrs [IS ...

Merck & Company Inc. is riding a wave of positive sentiment, signaling a potential near and mid-term breakout. As the current ...

The company will be heavily investing over the next decade to build a new biopharmaceutical facility in Holly Springs, NC, ...

The combination will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.